Science this week
New developments, newest first. Each is also written into the topic it belongs to.
First patient treated with an iPS-cell therapy for Parkinson's disease
Japan's health ministry gave conditional, time-limited approval on 6 March 2026 to two products made from induced pluripotent stem cells: Amchepry (Sumitomo Pharma), in which iPS cells from healthy donors are turned into the precursors of dopamine-producing neurons and transplanted into the brain in Parkinson's disease, and ReHeart (Cuorips), sheets of heart-muscle cells for severe heart failure. Sumitomo Pharma said on 30 October 2026 that the first transplant under that approval had been carried out at Kyoto University Hospital.
Why it matters: These are the first iPS-cell products anywhere cleared for sale, about twenty years after the reprogramming work that won Yamanaka the Nobel Prize in 2012, and they test the central claim of the iPS route: that replacement cells can be supplied without using an embryo. The approval is conditional and time-limited, which means efficacy is not yet established. The companies must keep following patients for seven years before full approval can be considered, so this is the beginning of the evidence and not the end of it.
Remember: iPS cells are ordinary adult cells reprogrammed to an embryonic-like state, so no embryo is destroyed and the cells can come from a donor rather than the patient. Amchepry supplies the dopamine-producing neurons that Parkinson's disease destroys; the Kyoto University trial behind it treated seven patients aged 50 to 69 with 5 or 10 million cells. Conditional approval is not proof of cure.
Source: Sumitomo Pharma announcement, reported by AFP, November 2026
Nobel Prize in Physiology or Medicine 2026: light-gated ion channels and optogenetics
The 2026 prize went to Karl Deisseroth (United States) and Peter Hegemann and Georg Nagel (Germany) for their discoveries concerning light-gated ion channels and optogenetics. Hegemann and Nagel established that algae carry channelrhodopsins, membrane proteins that open an ion channel when light falls on them. Deisseroth put the gene for such a protein into nerve cells, so that a pulse of light can switch a chosen neuron on or off.
Why it matters: The method rests on two facts from this chapter rather than on neuroscience alone: a gene taken from an alga can be read by a mammalian cell because the genetic code is shared, and a virus can be used to carry that gene into one chosen type of cell. It is also a clear case of a single protein in the membrane doing a specific job, which is what makes a cell more than a bag of chemicals.
Remember: Channelrhodopsin comes from algae; the gene is delivered into neurons by a viral vector; light then controls when that cell fires. Recent medicine prizes: 2026 optogenetics (Deisseroth, Hegemann, Nagel); 2025 peripheral immune tolerance (Brunkow, Ramsdell, Sakaguchi); 2024 microRNA (Ambros, Ruvkun).
RAPP-8 begins fuel loading at Rawatbhata
NPCIL began initial fuel loading in unit 8 of the Rajasthan Atomic Power Project (RAPP-8), a 700 MWe indigenous PHWR at Rawatbhata, on 19 September 2026 after permission from the Atomic Energy Regulatory Board.
Why it matters: It is the fourth indigenous 700 MWe PHWR to reach this stage, part of a planned fleet of 16 built in 'fleet mode'. These units supply most of the growth to about 22 GW by 2031-32.
Remember: Sequence: fuel loading → first criticality → grid synchronisation → commercial operation. NPCIL expects commercial operation within 2026-27. RAPP-7 has been in commercial operation since April 2025.
Source: World Nuclear News, Sept 2026
Draft SHANTI Rules and Regulations released for consultation
The Department of Atomic Energy published draft SHANTI Rules, 2026 and draft SHANTI Regulations, 2026 on 14 August 2026, inviting comments until 4 September 2026. They propose a single composite licence covering a nuclear plant's construction, operation and decommissioning, a time limit for licensing decisions, and mandatory insurance or financial security for operators.
Why it matters: The SHANTI Act opens nuclear power to private and joint-venture operators, but it needs these rules to work. The 46 GW expected from entities other than NPCIL depends on them.
Remember: Act passed December 2025; draft rules August 2026; final rules and commencement still awaited (Nov 2026). Draft is not final.
Source: Department of Atomic Energy, public consultation notice
BARC's small modular reactors get sites and in-principle approval
The government told Parliament that BARC's 220 MWe Bharat Small Modular Reactor (BSMR-200), the 55 MWe SMR-55 and a high-temperature gas-cooled reactor of up to 5 MWth for hydrogen production have in-principle approval for engineering and construction. Tarapur is the site for the lead BSMR-200 and SMR-55 units.
Why it matters: These are the designs meant to deliver the Nuclear Energy Mission's target of at least five indigenous SMRs by 2033.
Remember: BSMR-200 and SMR-55: pressurised water reactors, lead units at Tarapur (Maharashtra). HTGCR: up to 5 MWth, for hydrogen, at BARC Vizag.
India reports 20 per cent ethanol blending, five years early
The government told Parliament in July 2026 that an average of 20 per cent ethanol blending in petrol, the E20 target, had been reached in the 2025-26 ethanol supply year, five years ahead of the original 2030 deadline and in line with the target advanced to 2025-26 by the 2022 amendment to the National Policy on Biofuels. Ethanol production capacity has grown several-fold since 2014, and output now runs ahead of what E20 itself requires.
Why it matters: It is the largest working example in India of a biological process at industrial scale: yeast fermenting sugars, with the feedstock decided by policy rather than by biology. That is also where the argument sits. The blending has been achieved almost entirely on the first-generation route, using sugarcane juice, molasses and grain, so the gains in import substitution are set against the diversion of food crops, the water demand of sugarcane and questions about older engines. Second-generation ethanol from crop residue would avoid the food objection, but the cellulose must first be broken into fermentable sugars, and that step has kept commercial-scale plants difficult to run.
Remember: E20 means 20 per cent ethanol in petrol. 1G ethanol comes from sugar and starch feedstocks, 2G from lignocellulosic residue requiring an extra breakdown step. The policy instrument is the National Policy on Biofuels 2018, amended in 2022 to advance the E20 target to 2025-26. Compressed biogas is a separate route, from anaerobic digestion, promoted under SATAT and GOBARdhan.
Source: The Wire, reporting the government's reply in Parliament, July 2026
Government sets out the roadmap to 100 GW of nuclear power
The Department of Atomic Energy told Parliament how the 100 GW target for 2047 is to be met: from 8.78 GW today to about 22 GW by 2031-32 as projects under way are completed; NPCIL then adds about 32 GW more (taking it to about 54 GW); the remaining 46 GW is to come from other public-sector companies, state governments, private firms and joint ventures.
Why it matters: It turns a headline target into a division of labour, and shows how much rests on new entrants under the SHANTI Act.
Remember: 8.78 → ~22 → 100 GW. 54 GW NPCIL; 46 GW others (not an SMR-only target).
Source: World Nuclear Association, India outlook (citing DAE reply, July 2026)
India and Australia finalise arrangement for uranium exports
At the third India–Australia Annual Summit in Melbourne on 9 July 2026, the two countries finalised the Administrative Arrangement under their 2014 civil nuclear cooperation agreement, enabling long-term exports of Australian uranium to India.
Why it matters: Australia holds the world's largest uranium resources but exports only to countries with a cooperation agreement and agreed accounting procedures. The arrangement adds a major supplier for India's expanding safeguarded fleet.
Remember: Agreement signed 2014, in force 2015; arrangement finalised 9 July 2026. Uranium stays under IAEA safeguards, for peaceful use only. Australia also restated support for India's NSG membership.
Source: PIB factsheet, 14 July 2026
NPT Review Conference ends without an agreed document
The 11th NPT Review Conference (New York, 27 April to 22 May 2026) closed without a consensus outcome document.
Why it matters: It is the third review conference in a row to fail (after 2015 and 2022), a sign of strain on the treaty at the centre of the non-proliferation system.
Remember: Review conferences are held every five years; the next is due in 2031. The last one to agree a final document was in 2010.
Source: UN press release, 22 May 2026
PFBR at Kalpakkam attains first criticality
The 500 MWe Prototype Fast Breeder Reactor reached first criticality on 6 April 2026: a controlled, self-sustaining chain reaction began for the first time.
Why it matters: It is India's entry into stage 2 of the three-stage programme. Construction began in 2004 against a 2010 target, so it also ends a long delay.
Remember: Designed by IGCAR; built and operated by BHAVINI. Fuel: uranium-plutonium MOX; a U-238 blanket breeds Pu-239. Criticality is not commercial operation.
India's bioeconomy reported at $195.3 billion for 2025
The India BioEconomy Report 2026, published by BIRAC under the Department of Biotechnology and compiled by ABLE, puts the bioeconomy at $195.3 billion in 2025, against $165.7 billion in 2024: a rise of about 18 per cent, and roughly 4.8 per cent of GDP. By segment: BioIndustrial $90.2 billion, BioPharma $64.5 billion, BioServices $26 billion, BioAgri $14.6 billion. The report counts 11,855 biotech startups, 1,780 of them added during 2025, and repeats the targets of $300 billion by 2030 and $1 trillion by 2047.
Why it matters: This is the figure usually quoted for the size of Indian biotechnology, so the current year's number matters. Its composition matters more. 'Bioeconomy' here means economic value arising from activity enabled by biology, which is why the largest segment, BioIndustrial, takes in items such as fermented beverages, animal feed and textile processing. The total therefore measures biology-enabled economic activity broadly rather than the size of advanced biotechnology, and BioAgri stays the smallest segment despite the weight of agriculture in the economy.
Remember: $195.3 bn in 2025 against $165.7 bn in 2024; about 4.8 per cent of GDP; segment order BioIndustrial > BioPharma > BioServices > BioAgri; targets $300 bn by 2030 and $1 trillion by 2047. Published by BIRAC under the Department of Biotechnology; the enabling policy is BioE3.
New START expires, leaving no US-Russia limits on nuclear arsenals
New START, the last nuclear arms control treaty between the United States and Russia, expired on 5 February 2026 with no successor agreement.
Why it matters: For the first time since the early 1970s, the two largest nuclear arsenals have no legally binding limits or inspections.
Remember: Signed 2010, extended once in 2021 for five years. It capped deployed strategic warheads at 1,550 for each side.
Source: ICAN, Feb 2026
SHANTI Act, 2025 replaces India's two main nuclear laws
Parliament passed the Sustainable Harnessing and Advancement of Nuclear Energy for Transforming India (SHANTI) Bill in December 2025, and it received Presidential assent. It repeals the Atomic Energy Act, 1962 and the Civil Liability for Nuclear Damage Act, 2010.
Why it matters: It allows limited private participation in nuclear power under regulatory oversight, gives the Atomic Energy Regulatory Board statutory recognition, and rewrites nuclear liability. Strategic materials and spent fuel management stay under government control.
Remember: Two laws repealed: Atomic Energy Act, 1962 and CLND Act, 2010. Operator liability is now graded by reactor size; recourse against suppliers only if a written contract provides for it or the damage was intentional.
Source: PIB, 19 Dec 2025
Indian patent for TnpB, a gene-editing protein a third the size of Cas9
ICAR announced in November 2025 that its Central Rice Research Institute at Cuttack had been granted a twenty-year Indian patent, 'Systems and Methods for Targeted Genome Editing in Plants', for editing with TnpB. TnpB is a transposon-associated nuclease of about 408 amino acids, roughly a third the size of Cas9 (1,000 to 1,400 amino acids) or Cas12a (about 1,300). The institute reports editing efficiency of up to 69 per cent in rice and in Arabidopsis, with multiplex editing and base editing also possible.
Why it matters: Size is the point. A smaller protein fits more easily into the viral vectors used to get editing machinery into a plant cell, which can avoid some of the tissue-culture steps that bulkier systems need. The second gain is legal rather than biological: TnpB is a different protein, so editing with it sits outside the Cas9 patents held abroad by the Broad Institute and by Corteva. For a country that wants to edit its own varieties and sell the seed, who owns the tool decides what a licence costs.
Remember: TnpB - ICAR-Central Rice Research Institute, Cuttack; twenty-year Indian patent reported in November 2025; about 408 amino acids, roughly one-third of Cas9; up to 69 per cent editing efficiency in rice (a monocot) and Arabidopsis (a dicot). A patent on a tool is not a released variety.
Source: ICAR, November 2025
Gene therapy · From rDNA to gene editing
BIRSA 101: an Indian gene-editing platform aimed at sickle cell disease
CSIR-IGIB launched BIRSA 101, described as India's first indigenous CRISPR-based gene therapy for sickle cell disease. It uses enFnCas9, an editing protein engineered at the institute rather than licensed from abroad: stem cells are taken from the patient, the gene is edited, and the cells are returned so that normal haemoglobin is produced. It was launched on 19 November 2025, named for the 150th birth anniversary of Birsa Munda, and a technology-transfer agreement was signed with Serum Institute of India for scale-up and trials.
Why it matters: Sickle cell disease is concentrated in tribal and central Indian districts, where the gene therapies approved abroad, priced at Rs 20 to 25 crore, are irrelevant in practice. An Indian editing protein matters for two separate reasons: it avoids the patent stack around Cas9, and it allows the cost of the whole procedure to be designed for Indian conditions. The platform is at the start of that road: a launch and a technology-transfer agreement are not an approved treatment, and the edited-stem-cell route still requires the demanding hospital procedure that goes with a bone-marrow transplant.
Remember: BIRSA 101 - CSIR-IGIB, launched 19 November 2025, named after Birsa Munda, aimed at sickle cell disease, built on the indigenous enFnCas9 protein, technology transferred to Serum Institute of India. Distinguish it from Casgevy, the CRISPR therapy approved abroad in 2023 for sickle cell disease and beta-thalassaemia. It supports the goal of a sickle-cell-free India by 2047.
Source: BioSpectrum India, November 2025
China's molten-salt reactor converts thorium into uranium fuel
The Shanghai Institute of Applied Physics (Chinese Academy of Sciences) announced that its experimental TMSR-LF1 reactor at Wuwei, Gansu, had achieved the first conversion of thorium into uranium fuel in a molten-salt reactor.
Why it matters: It is experimental evidence for a thorium route different from India's solid-fuel, three-stage approach: the fuel is dissolved in molten salt that also carries the heat.
Remember: TMSR-LF1: 2 MW thermal; criticality Oct 2023; driven by uranium enriched to just under 20%. A small research reactor, not a power plant.
Source: World Nuclear News, Nov 2025
Nobel Prize in Physiology or Medicine 2025: peripheral immune tolerance
Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi shared the prize for their discoveries concerning peripheral immune tolerance. Sakaguchi identified a class of T cells that hold the immune system back rather than attack, now called regulatory T cells. Brunkow and Ramsdell traced a severe autoimmune disease in mice to the gene Foxp3, which was then shown to be the gene those cells depend on.
Why it matters: It explains why the immune system does not ordinarily attack the body that houses it, and that explanation cuts both ways in medicine. Too little restraint appears as autoimmune disease and as rejection of a transplant. Too much restraint is one reason tumours survive, because a tumour that attracts regulatory T cells is shielded from attack. Several therapies in this topic, from checkpoint inhibitors to cell therapies, are attempts to shift that balance deliberately.
Remember: Regulatory T cells (Tregs) and the Foxp3 gene they depend on. Peripheral tolerance acts on mature immune cells outside the thymus, as against central tolerance, which removes self-reactive cells inside it. 2025 medicine prize: Brunkow, Ramsdell, Sakaguchi.
Eight children born after mitochondrial donation in the United Kingdom
A Newcastle team reported in the New England Journal of Medicine that eight babies had been born to seven women carrying disease-causing mutations in mitochondrial DNA, out of 22 patients treated. The technique used, pronuclear transfer, moves the nuclear genome of a fertilised egg into a donor egg that has healthy mitochondria. Faulty mitochondrial DNA was undetectable or reduced by 95 to 100 per cent in six of the children and by 77 to 88 per cent in the other two.
Why it matters: This is the clearest demonstration of the difference between the two genomes a person carries. The child's nuclear DNA comes from its two parents; only the mitochondrial DNA, about 0.1 per cent of the total and carrying 37 genes, comes from the donor, which is why the term 'three-parent baby' misleads. The results are not uniformly clean: a measurable mutation load returned in a few of the children, which is why follow-up continues. The United Kingdom licensed the procedure in 2015 and it remains prohibited in many countries, including the United States and France.
Remember: Mitochondria are inherited only from the mother, so mitochondrial disease descends the maternal line. Mitochondrial donation replaces the mitochondria, not the nuclear genes, so it prevents transmission rather than treating a patient. Newcastle, NEJM, July 2025: 22 patients, eight children, mutation load cut by 77 to 100 per cent. Licensed in the UK since 2015.
Source: Newcastle University, July 2025
GM and edited crops · From rDNA to gene editing
India releases its first two genome-edited rice varieties
The Union Agriculture Minister released two genome-edited rice varieties developed by ICAR on 4 May 2025 in New Delhi. DRR Dhan 100 (Kamala), from the Indian Institute of Rice Research at Hyderabad, was bred from Samba Mahsuri by editing a gene that limits grain number; it matures about 15 to 20 days earlier, at around 130 days, with a reported yield gain of roughly 19 to 25 per cent, and the shorter duration saves about three irrigations. Pusa DST Rice 1, from the Indian Agricultural Research Institute at New Delhi, was bred from MTU 1010 by editing the DST gene and is aimed at tolerance of salinity and alkalinity. Both used SDN-1 editing, in which the cell's own repair of a cut introduces the change and no foreign gene remains.
Why it matters: Here the regulatory distinction drawn in this chapter has a concrete consequence. Because SDN-1 and SDN-2 edited plants carrying no foreign DNA were exempted from the GM rules in 2022, these varieties could be released through the ordinary varietal channel, while GM mustard and Bt brinjal remain stalled. The claim to be first should also be stated carefully: India is the first country to release genome-edited varieties of rice, not the first to release a genome-edited crop. And a released variety is not yet a planted one; seed multiplication decides when farmers actually sow it.
Remember: DRR Dhan 100 (Kamala), from Samba Mahsuri - earlier maturity, more grains per panicle, three irrigations saved. Pusa DST Rice 1, from MTU 1010 - salinity and alkalinity tolerance. Both are SDN-1 edits carrying no foreign gene, which is why they fall outside the GM approval route. Released 4 May 2025.
Identity markers · Reading the genome
Genome India: first findings from nearly 10,000 Indian genomes
The Genome India project, launched in 2020 by the Department of Biotechnology and run by more than twenty institutions, collected samples from about 20,000 people and sequenced whole genomes from 10,074 of them, drawn from 85 population groups, 32 tribal and 53 non-tribal. The dataset was released for research in January 2025, and the first findings were published as a Comment in Nature Genetics on 8 April 2025, based on 9,772 individuals after two populations were excluded. About 180 million genetic variants were catalogued, 130 million on the autosomes and 50 million on the X and Y chromosomes. The sequence data sit in the Indian Biological Data Centre at the Regional Centre for Biotechnology, Faridabad.
Why it matters: Most of what medicine knows about which DNA letters matter was learnt from European populations, so a variant that is common in India may be missing from the reference databases a clinical laboratory consults. Closing that gap is the point of the project, and India's endogamous population structure means some variants are confined to single communities, which is exactly what a global database cannot supply. What the catalogue does not yet do is treat anyone: variants become useful only once particular ones are tied to particular conditions and drug responses, and the April publication was a Comment reporting progress rather than a full analysis.
Remember: Genome India - Department of Biotechnology, launched 2020, more than 20 institutions; 10,074 genomes sequenced from 85 population groups (32 tribal, 53 non-tribal); first findings on 9,772 individuals, about 180 million variants (130 million autosomal, 50 million on sex chromosomes); data at the Indian Biological Data Centre, Faridabad. Distinguish it from IndiGen, the CSIR project that sequenced about 1,000 Indian genomes.
Source: The Hindu, April 2025
NIF sets a fusion record: 8.6 MJ out from 2.08 MJ of laser energy
The National Ignition Facility in the US produced 8.6 megajoules of fusion energy from 2.08 megajoules of laser energy delivered to the target, a target gain of about 4.1.
Why it matters: It more than doubles NIF's first ignition result of December 2022 (3.15 MJ from 2.05 MJ) and shows ignition can be repeated.
Remember: The gain is measured at the target. Powering the lasers draws roughly 300 MJ from the grid, so no fusion device yet produces net electricity.
Source: Lawrence Livermore National Laboratory annual report 2025
Budget 2025-26 launches the Nuclear Energy Mission
A Nuclear Energy Mission with an outlay of Rs 20,000 crore for research and development of small modular reactors; at least five indigenously developed SMRs to be operational by 2033. The Budget also set the goal of 100 GW of nuclear capacity by 2047.
Why it matters: It sets the targets against which India's nuclear expansion, and the opening to private players, will be judged.
Remember: Rs 20,000 crore; 5 SMRs by 2033; 100 GW by 2047. Installed capacity in 2026: 8.78 GW.
Source: PIB, 3 Feb 2025
ITER resets its schedule: research operations from 2034
ITER's new baseline targets the start of research operations in 2034 and deuterium-tritium operation in 2039. The earlier 2016 plan had aimed for first plasma in 2025.
Why it matters: Notes saying ITER would be complete by 2025 are out of date.
Remember: ITER is a research device, not a power plant. It is in southern France, and India is a member.
Source: ITER Organization, Jul 2024